Physician profile
Bora Toklu
NPI 1508019456
$3,805.42
in general payments reported to CMS, 2019-2025
26 companies · $377 in 2025
The $377 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,612 · 2020: $308 · 2021: $943 · 2022: $95.14 · 2023: $295 · 2024: $176 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $979.08 | 2019 | |
| Boston Scientific Corporation | $565.37 | 2019-2025 | Watchman Flx, Watchman, Lithovue Empower |
| Janssen Pharmaceuticals, INC | $520.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $383.20 | 2019-2024 | Farxiga |
| Medtronic, INC. | $246.42 | 2021-2022 | |
| Amgen INC. | $127.10 | 2019-2023 | Repatha |
| Acist Medical Systems, INC. | $126.78 | 2019 | |
| Medtronic Vascular, INC. | $116.47 | 2019-2020 | |
| Stryker Corporation | $89.25 | 2025 | Flowtriever, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $71.98 | 2022-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $64.34 | 2020-2021 | |
| Edwards Lifesciences Corporation | $60.24 | 2021-2025 | Sapien 3 Ultra Resilia |
| Penumbra, INC. | $59.91 | 2025 | Indigo System |
| Heartflow, INC. | $57.01 | 2019 | |
| Irhythm Technologies, INC. | $53.90 | 2023 | Zio Xt Patch |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $50.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $44.96 | 2023-2025 | |
| Pfizer INC. | $40.54 | 2020-2021 | |
| United Therapeutics Corporation | $30.05 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.79 | 2021 | |
| Merck Sharp & Dohme LLC | $16.18 | 2023 | Belsomra, Steglatro |
| Lilly USA, LLC | $15.97 | 2024 | Jardiance, Zepbound |
| Arbor Pharmaceuticals, INC. | $14.83 | 2021 | |
| Novo Nordisk INC | $14.79 | 2021 | |
| Cardinal Health 200 LLC | $14.78 | 2019 | |
| Amryt Pharma Holdings LTD | $14.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bora Toklu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.